A. Ai Yamamoto, Ph.D.
The acclaimed Columbia neuroscientist, a leading researcher in autophagy–or protein trafficking–in Huntington’s, has turned her talents to ALS. Project ALS recruited Dr. Yamamoto and Noah Depoure, Ph.D., a quantitative biochemist at Cornell, to characterize protein aggregation in ALS. One year in to the study, Yamamoto has identified a possible strategy for augmenting protein turnover in ALS.
In 2020, Cathy and Richard called Project ALS after hearing about the development of a novel antisense oligonucleotide (ASO) therapy for people living with FUS ALS. So was born NextGen ALS, a Weber family initiative in collaboration with Project ALS that is committed to raising funds for targeted research toward treatments and cures for genetic forms of ALS.